4,539 research outputs found
COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?
Serum levels of acyl-carnitines along the continuum from normal to Alzheimer's dementia
This study aimed to determine the serum levels of free L-carnitine, acetyl-L-carnitine and 34 acyl-L-carnitine in healthy subjects and in patients with or at risk of Alzheimer's disease. Twenty-nine patients with probable Alzheimer's disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry. The concentrations of acetyl-L-carnitine progressively decreased passing from healthy subjects group (mean±SD, 5.6±1.3 Όmol/L) to subjective memory complaint (4.3±0.9 Όmol/L), mild cognitive impairment (4.0±0.53 Όmol/L), up to Alzheimer's disease (3.5±0.6 Όmol/L) group (p<0.001). The differences were significant for the comparisons: healthy subjects vs. subjective memory complaint, mild cognitive impairment or Alzheimer's disease group; and subjective memory complaint vs. Alzheimer's disease group. Other acyl-carnitines, such as malonyl-, 3-hydroxyisovaleryl-, hexenoyl-, decanoyl-, dodecanoyl-, dodecenoyl-, myristoyl-, tetradecenoyl-, hexadecenoyl-, stearoyl-, oleyl- and linoleyl-L-carnitine, showed a similar decreasing trend, passing from healthy subjects to patients at risk of or with Alzheimer's disease. These results suggest that serum acetyl-L-carnitine and other acyl-L-carnitine levels decrease along the continuum from healthy subjects to subjective memory complaint and mild cognitive impairment subjects, up to patients with Alzheimer's disease, and that the metabolism of some acyl-carnitines is finely connected among them. These findings also suggest that the serum levels of acetyl-L-carnitine and other acyl-L-carnitines could help to identify the patients before the phenotype conversion to Alzheimer's disease and the patients who would benefit from the treatment with acetyl-L-carnitine. However, further validation on a larger number of samples in a longitudinal study is needed before application to clinical practice
p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up
p53 gene alterations are among the most common events observed in colorectal cancer, and are accompanied frequently by DNA aneuploidy and high proliferative activity. The prognostic significance of such mutations remains controversial. We prospectively evaluated the prognostic significance of p53 mutations, DNA-ploidy, and S phase fraction (SPF) in a consecutive series of 160 colorectal cancer patients (median follow-up 71 months). Tumor DNA was screened for p53 mutations by PCR/single-strand conformational polymorphism/sequencing. DNA-ploidy and SPF were assessed by DNA flow cytometry. p53 mutations were detected in 68 of 160 (42.5%) cases. In 56% (38 of 68) of these, p53 mutations were found in conserved areas of the gene and in 44% (30 of 68 cases) outside the conserved regions. Eighteen of the 68 cases (26%) had mutations in the L3 loop, 11 of 68 (16%) in the L1 loop-sheet-\u3b1 helix motif, and 39 of 68 (58%) outside L3 and loop-sheet-\u3b1 helix. Seventy-five percent of the cases (120 of 160) showed DNA aneuploidy, whereas 18% of these (22 of 120) were multiclonal. The major independent predictors for both disease relapse and death were advanced Dukes' stage, p53 mutations affecting L3 loop, DNA-aneuploid tumors, and high SPF (>18.5%). Our results show that mutations in L3 functional domain, more than any mutations, are important biological indicators to predict the outcome of patients indicating that these mutations have biological relevance in terms of colorectal cancer disease course
On stable higher spin states in Heterotic String Theories
We study properties of 1/2 BPS Higher Spin states in heterotic
compactifications with extended supersymmetry. We also analyze non BPS Higher
Spin states and give explicit expressions for physical vertex operators of the
first two massive levels. We then study on-shell tri-linear couplings of these
Higher Spin states and confirm that BPS states with arbitrary spin cannot decay
into lower spin states in perturbation theory. Finally, we consider scattering
of vector bosons off higher spin BPS states and extract form factors and
polarization effects in various limits.Comment: 38 page
Expected performance of the ASTRI-SST-2M telescope prototype
ASTRI (Astrofisica con Specchi a Tecnologia Replicante Italiana) is an
Italian flagship project pursued by INAF (Istituto Nazionale di Astrofisica)
strictly linked to the development of the Cherenkov Telescope Array, CTA.
Primary goal of the ASTRI program is the design and production of an end-to-end
prototype of a Small Size Telescope for the CTA sub-array devoted to the
highest gamma-ray energy region. The prototype, named ASTRI SST-2M, will be
tested on field in Italy during 2014. This telescope will be the first
Cherenkov telescope adopting the double reflection layout in a
Schwarzschild-Couder configuration with a tessellated primary mirror and a
monolithic secondary mirror. The collected light will be focused on a compact
and light-weight camera based on silicon photo-multipliers covering a 9.6 deg
full field of view. Detailed Monte Carlo simulations have been performed to
estimate the performance of the planned telescope. The results regarding its
energy threshold, sensitivity and angular resolution are shown and discussed.Comment: In Proceedings of the 33rd International Cosmic Ray Conference
(ICRC2013), Rio de Janeiro (Brazil). All CTA contributions at arXiv:1307.223
Prostate health index and multiparametric mri: Partners in crime fighting overdiagnosis and overtreatment in prostate cancer
Widespread use of PSA as the standard tool for prostate cancer (PCa) diagnosis led to a high rate of overdiagnosis and overtreatment. In this study, we evaluated the performance of the prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) for the prediction of positive biopsy and of highâgrade PCa at radical prostatectomy (RP). To this end, we prospectively enrolled 196 biopsyânaĂŻve patients who underwent mpMRI. A subgroup of 116 subjects with biopsyâproven PCa underwent surgery. We found that PHI significantly outperformed both PIâRADS score (difference in AUC: 0.14; p < 0.001) and PHI density (difference in AUC: 0.08; p = 0.002) in the ability to predict positive biopsy with a cutâoff value of 42.7 as the best threshold. Conversely, comparing the performance in the identification of clinically significant prostate cancer (csPCa) at RP, we found that PHI â„61.68 and PIâRADS score â„4 were able to identify csPCa (Gleason score â„7 (3 + 4)) both alone and added to a base model including age, PSA, fPSAâto-tPSA ratio and prostate volume. In conclusion, PHI had a better ability than PIâRADS score to predict positive biopsy, whereas it had a comparable performance in the identification of pathological csPCa
- âŠ